Stock Scorecard



Stock Summary for Beam Therapeutics Inc (BEAM) - $17.82 as of 8/18/2025 12:16:12 PM EST

Total Score

10 out of 30

Safety Score

40 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BEAM

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BEAM

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BEAM

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BEAM

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BEAM (40 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 9
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 5
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BEAM

Pfizer's Investigational Drug Flunks Late-Stage For Sickle Cell Disease - Pfizer ( NYSE:PFE ) 8/15/2025 7:35:00 PM
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? 8/12/2025 3:40:00 PM
BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark 8/6/2025 3:51:00 PM
Beam Therapeutics Inc. ( BEAM ) Reports Q2 Loss, Misses Revenue Estimates 8/5/2025 12:15:00 PM
Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results 7/31/2025 11:05:00 AM
Vir Biotechnology, Inc. ( VIR ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release 7/30/2025 2:00:00 PM
3 Genomics Stocks Worth Adding to Your Portfolio in 2025 7/30/2025 1:44:00 PM
Will Beam Therapeutics Inc. ( BEAM ) Report Negative Q2 Earnings? What You Should Know 7/29/2025 2:00:00 PM
Beam Therapeutics ( BEAM ) Surges 5.7%: Is This an Indication of Further Gains? 7/10/2025 2:02:00 PM
Innovation ETF ( ARKK ) Hits New 52-Week High 7/9/2025 2:45:00 PM

Financial Details for BEAM

Company Overview

Ticker BEAM
Company Name Beam Therapeutics Inc
Country USA
Description Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Sector Name LIFE SCIENCES
Industry Name BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Most Recent Quarter 6/30/2025
Next Earnings Date 11/10/2025

Stock Price History

Last Day Price 17.82
Price 4 Years Ago 79.69
Last Day Price Updated 8/18/2025 12:16:12 PM EST
Last Day Volume 2,148,411
Average Daily Volume 2,522,773
52-Week High 35.25
52-Week Low 13.53
Last Price to 52 Week Low 31.71%

Valuation Measures

Trailing PE N/A
Industry PE 37.31
Sector PE 59.06
5-Year Average PE -10.04
Free Cash Flow Ratio 6.39
Industry Free Cash Flow Ratio 19.66
Sector Free Cash Flow Ratio 30.26
Current Ratio Most Recent Quarter 6.75
Total Cash Per Share 2.79
Book Value Per Share Most Recent Quarter 10.70
Price to Book Ratio 1.70
Industry Price to Book Ratio 7.30
Sector Price to Book Ratio 26.93
Price to Sales Ratio Twelve Trailing Months 29.59
Industry Price to Sales Ratio Twelve Trailing Months 51.92
Sector Price to Sales Ratio Twelve Trailing Months 15.21
Analyst Buy Ratings 10
Analyst Strong Buy Ratings 3

Share Statistics

Total Shares Outstanding 101,162,000
Market Capitalization 1,802,706,840
Institutional Ownership 101.78%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -184.28%
Reported EPS 12 Trailing Months -4.50
Reported EPS Past Year -2.24
Reported EPS Prior Year -4.58
Net Income Twelve Trailing Months -398,583,000
Net Income Past Year -376,742,000
Net Income Prior Year -132,527,000
Quarterly Revenue Growth YOY -28.10%
5-Year Revenue Growth 412.30%
Operating Margin Twelve Trailing Months -1,419.00%

Balance Sheet

Total Cash Most Recent Quarter 282,132,000
Total Cash Past Year 281,967,000
Total Cash Prior Year 435,895,000
Net Cash Position Most Recent Quarter 280,345,000
Net Cash Position Past Year 278,960,000
Long Term Debt Past Year 3,007,000
Long Term Debt Prior Year 3,007,000
Total Debt Most Recent Quarter 1,787,000
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 733,545,000
Total Stockholder Equity Prior Year 981,329,000
Total Stockholder Equity Most Recent Quarter 1,046,813,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -355,572,000
Free Cash Flow Per Share Twelve Trailing Months -3.51
Free Cash Flow Past Year -356,192,000
Free Cash Flow Prior Year -182,927,000

Options

Put/Call Ratio 0.06
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.60
MACD Signal -0.23
20-Day Bollinger Lower Band 14.41
20-Day Bollinger Middle Band 18.12
20-Day Bollinger Upper Band 21.83
Beta 2.22
RSI 41.83
50-Day SMA 22.94
150-Day SMA 28.65
200-Day SMA 36.69

System

Modified 8/15/2025 6:39:22 PM EST